Figure 7. In vivo depletion of CD19-DTYMKΔ-modified T-Rapa cells by AZT therapy. T-Rapa cells were transduced with CD19-DTYMKΔ LV (MOI 110) and injected intravenously into NSG mice (1 million cells/ mouse). For the first 7 d after adoptive transfer, recipients were treated with either AZT (25 mg/kg/2×/day) or PBS. Thirty days later, human T cell engraftment was analyzed in the spleen. Splenocytes were counted and stained with anti-human CD19 and anti-human CD45 antibodies. The frequencies of human CD45⁺CD19⁺ cells were examined by flow cytometry. Results shown are absolute number of cells per spleen and mean (± SEM) of 5 mice per group (*p < 0.0288).